GSK settlement keeps it on course to remove Zantac overhang

GSK settlement keeps it on course to remove Zantac overhang by early 2024, analyst says

GSK PLC's (LSE:GSK, NYSE:GSK) latest out-of-court Zantac deal is important to the ongoing "overhang" over the investment case, Citigroup said. The US...

Related Keywords

California , United States , Cantlay Harper , Citigroup , ,

© 2025 Vimarsana